Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABFRA:61MA -0.22%91 Buyback Yield % is -0.03 as of Jul. 17, 2026. GuruFocus rates FRA:61MA with a GF Score™ of 91/100 and a GF Value™ of €50.10 (Fairly Valued). Among 347 Medical Devices & Instruments companies, MedCap AB ranks better than 61.1% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for MedCap AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:61MA vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, MedCap AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where MedCap AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (FRA:61MA) has a Buyback Yield % of -0.03 as of Jul. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MedCap AB and its competitors. According to the industry distribution chart, MedCap AB ranks #135 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 38.9%.
Is MedCap AB's Buyback Yield % too high?
MedCap AB's current Buyback Yield % is -0.03. Based on the distribution chart, MedCap AB ranks #135 out of 347 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #135 out of 347 companies for Buyback Yield %. This puts MedCap AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MedCap AB and its competitors. MedCap AB's current Buyback Yield % is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €50.10, compared to a current price of €45.54 — trading 9.1% below its estimated fair value. The current Buyback Yield % is -0.03. MedCap AB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current Buyback Yield % is -0.03 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (FRA:61MA) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of €45.54 is trading 9.1% below its estimated GF Value™ of €50.10.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for FRA:61MA:
Buyback Yield %: -0.03
GF Value™: €50.10 vs. price of €45.54 (9.1% below fair value)
No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score
Get the complete analysis for FRA:61MA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61MA has been successfully added to your 
